Oncosil Medical Ltd
ASX:OSL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Oncosil Medical Ltd
Common Shares Outstanding
Oncosil Medical Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Oncosil Medical Ltd
ASX:OSL
|
Common Shares Outstanding
AU$14.2m
|
CAGR 3-Years
64%
|
CAGR 5-Years
40%
|
CAGR 10-Years
28%
|
|
|
Genetic Technologies Ltd
ASX:GTG
|
Common Shares Outstanding
AU$145.4m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
-17%
|
|
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
Common Shares Outstanding
AU$163.8m
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
T
|
Trajan Group Holdings Ltd
ASX:TRJ
|
Common Shares Outstanding
AU$152.4m
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Cryosite Ltd
ASX:CTE
|
Common Shares Outstanding
AU$48.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
E
|
EZZ Life Science Holdings Ltd
ASX:EZZ
|
Common Shares Outstanding
AU$47.2m
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
Oncosil Medical Ltd
Glance View
OncoSil Medical Ltd. develops and commercializes neurology services, including those for pancreatic cancer. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2005-08-15. The firm is focused on unresectable locally advanced pancreatic cancer (LAPC). The firm's lead product, OncoSil, is a single-use brachytherapy internal radiation device used to deliver a pre-determined dose of beta radiation directly into cancerous tissue. The OncoSil consists of microparticles that contain a radioisotope phosphorous-32 and a formulated diluent, which acts as a carrier to facilitate the implantation of the microparticles into the target tissue. The company enables doctors to target a greater radiation dose directly to the tumor, while sparing surrounding critical organs. The OncoSil device is used for the treatment of unresectable LAPC and is used in conjunction with chemotherapy.
See Also
What is Oncosil Medical Ltd's Common Shares Outstanding?
Common Shares Outstanding
14.2m
AUD
Based on the financial report for Dec 31, 2025, Oncosil Medical Ltd's Common Shares Outstanding amounts to 14.2m AUD.
What is Oncosil Medical Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
28%
Over the last year, the Common Shares Outstanding growth was 23%. The average annual Common Shares Outstanding growth rates for Oncosil Medical Ltd have been 64% over the past three years , 40% over the past five years , and 28% over the past ten years .
